Interested in specific Information?

Filter what you see here

General MM

Quick poll

Response outcomes in patients with newly diagnosed multiple myeloma

Response outcomes in patients with newly diagnosed multiple myeloma

Closes Mar 22, 2019

Relapsed/refractory patients

Quick poll

Patient outcomes in multiple myeloma refractory to CD38 monoclonal…

Closes Mar 22, 2019

Relapsed/refractory patients

Quick poll

FDA places partial clinical hold on trials involving venetoclax in…

Closes Mar 19, 2019

General MM

Quick poll

Impact of abnormal pulmonary function on outcomes in patients with newly…

Impact of abnormal pulmonary function on outcomes in patients with newly diagnosed multiple myeloma

Closes Mar 14, 2019

Patients eligible for transplant,   Patients non-eligible for transplant,  Relapsed/refractory patients

Quick poll

Results from the LYRA study: daratumumab, bortezomib, cyclophosphamide and…

Closes Mar 13, 2019

Relapsed/refractory patients

Quick poll

NICE to make daratumumab, bortezomib and dexamethasone triplet available…

Closes Mar 12, 2019

Relapsed/refractory patients

Quick poll

TCT Meeting 2019 | Nicotinamide-expanded related donor natural killer…

TCT Meeting 2019 | Nicotinamide-expanded related donor natural killer cells for the treatment of relapsed/refractory multiple myeloma and…

Closes Mar 12, 2019

Relapsed/refractory patients

Quick poll

A sub-group analysis from the ENDEAVOR study: health-related quality of…

Closes Mar 8, 2019

General MM

Quick poll

The impact of pre-existing monoclonal gammopathy on patient outcome in…

Closes Mar 7, 2019

Relapsed/refractory patients

Quick poll

Clarithromycin, pomalidomide and dexamethasone in patients with relapsed…

Clarithromycin, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: results from a phase II study

Closes Mar 5, 2019

Patients eligible for transplant

Quick poll

Results of the phase III VCAT study: subcutaneous bortezomib, thalidomide…

Closes Mar 1, 2019

Relapsed/refractory patients

Quick poll

Top-line results from the phase II study of CLR 131 – CLOVER-1

Closes Feb 28, 2019

Relapsed/refractory patients

Quick poll

Update from the phase III COLUMBA (MMY3012) study 

Update from the phase III COLUMBA (MMY3012) study 

Closes Feb 28, 2019

Relapsed/refractory patients

Quick poll

Update: FDA ODAC delays approval of selinexor until more data are available

Closes Feb 27, 2019

General MM

Quick poll

Carfilzomib and dexamethasone (Kd) therapy in patients with newly…

Closes Feb 26, 2019
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Congress Coverage

General MM,Patients eligible for transplant,Patients non-eligible for transplant,Relapsed/refractory patients

CAR T Cell Meeting 2019 | CAR T in multiple myeloma: when to use CAR T

Feb 20, 2019 , Expert Opinion
General MM,Patients eligible for transplant,Patients non-eligible for transplant,Relapsed/refractory patients

CAR T Cell Meeting 2019 | CAR T-cell therapy in multiple myeloma: the latest clinical data

Feb 19, 2019

Latest Biology

Latest Drug Updates

Relapsed/refractory patients

Top-line results from the phase II study of CLR 131 – CLOVER-1

Feb 28, 2019

Recently updated Licenses

Where we are next

45th Annual Meeting of the EBMT

March 24 – 27, 2019 | Frankfurt, Germany

The Multiple Myeloma Hub will be attending the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT) to be held in Frankfurt, Germany, in March 2019. The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates on the hottest topics in hematology. Stay tuned to follow our first-hand coverage.

#mmsm

Event Website

Map Data
Map data ©2019 GeoBasis-DE/BKG (©2009), Google
Map DataMap data ©2019 GeoBasis-DE/BKG (©2009), Google
Map data ©2019 GeoBasis-DE/BKG (©2009), Google

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology